Expert Insight and Future Perspectives for Follicular Lymphoma
Panelists close the discussion by offering insights and future perspectives on the treatment landscape for follicular lymphoma.
Treatment Approaches for R/R Follicular Lymphoma in the 3L and Beyond
An expert discussion surrounding the evolving treatment landscape for relapsed or refractory follicular lymphoma in the third-line setting and beyond.
Strategies for AE Management with Bispecific Antibodies
Faculty review potential adverse events (AEs) seen in patients receiving treatment with bispecific antibodies and discuss preferred strategies for AE management.
Considerations and Challenges Surrounding CAR-T Therapy and Bispecifics
Expert oncologists offer considerations for the use of CAR-T therapy and bispecific antibodies in follicular lymphoma and discuss potential challenges that may limit the use of these agents in clinical practice.
Role of CAR-T Therapy in R/R Follicular Lymphoma
An overview of the evolving role of CAR-T therapy in patients with relapsed or refractory follicular lymphoma.
Patient Profile 2: R/R Follicular Lymphoma with Early Disease Progression
Panelists review the previously presented patient case and discuss alternative treatment strategies in early disease progression with expert insight on preferred treatment approaches for this setting.
Follow-up Monitoring Strategies in R/R Follicular Lymphoma
Expert oncologists discuss best practices surrounding treatment follow-up and monitoring for patients with relapsed or refractory follicular lymphoma.
Role of PI3K Inhibitors in R/R Follicular Lymphoma
Faculty highlight recent changes in treatment guidelines surrounding the use of PI3K inhibitors in follicular lymphoma and discuss the evolving role of these agents in the treatment landscape.
Tazemetostat: Targeting EZH2 in R/R Follicular Lymphoma
Hematologist/oncologists describe the rationale for treatment approaches targeting EZH2 and discuss recent guideline updates surrounding the role of tazemetostat and EZH2 testing in patients with follicular lymphoma.
AUGMENT: Lenalidomide plus Rituximab in R/R Follicular Lymphoma
Experts review data updates from the AUGMENT trial and discuss potential clinical implications of these study findings.
Evolving Treatment Strategies for R/R Follicular Lymphoma
An overview of available treatment options for relapsed or refractory follicular lymphoma and with considerations for treatment selection and expert insight on preferred treatment approaches in the second-line setting.
Patient Scenario 1: 65-Year-old Woman with R/R Follicular Lymphoma
A panel of experts present that case of a 65-year-old woman with follicular lymphoma and discuss potential approaches for treatment in the relapsed or refractory setting.
The Evolution of the Treatment Landscape for Follicular Lymphoma
Expert oncologists discuss the evolving treatment landscape for follicular lymphoma and highlight key advances that have contributed to improved treatment options.
Physician Assistant Details Importance of AE Management in Follicular Lymphoma
The education of patients on identifying and reporting adverse effects is a critical part of effective toxicity management.
Examining the Role of the Physician Assistant in Follicular Lymphoma
One role of a physician assistant is to help patients understand their treatment and the results they’re presented with.
Targeted Therapies Are a Viable Option in Follicular Lymphoma Treatment
Adverse effect management is a concern for clinicians when administering follicular lymphoma treatment, and the use of targeted pathways may help mitigate them.